2017Zhonghua gan-dan waike zazhiRequires access

Percutaneous transhepatic intrahepatic portosystemic shunt for treatment of portal hypertension due to chronic portal vein occlusion after splenectomy

Junyang Luo, Mingan Li, Haofan Wang, Chun‐Ying Wu, Zhengran Li, Jiesheng Qian, Shouhai Guan, Mingsheng Huang

Open publisher page 0 citations

Abstract

Objective To study the feasibility and efficacy of percutaneous transhepatic intrahepatic portosystemic shunt (PTIPS) in patients with portal hypertension due to chronic portal vein occlusion after splenectomy. Methods 27 patients who had portal hypertension due to chronic portal vein occlusion after splenectomy underwent PTIPS between December 2010 and March 2015. These patients were enrolled in this retrospective study. The success rates, efficacy, and complications were evaluated. Significance in the differences in the portosystemic pressure gradient (PPG) as measured before and after PTIPS procedure was assessed. Results PTIPS was successfully carried out in 25 patients but failed in 2. No fatal procedural complications were observed. The mean PPG dropped from (22.3±5.7) mmHg to (12.4±3.1) mmHg after successful PTIPS (1 mmHg=0.133 kPa, P<0.05). The median follow-up in the 25 patients with successful PTIPS were 22 months and there were 3 (12.0%) deaths from liver failure due to severe cirrhosis, and 1 death (4.0%) from stroke during the follow-up period. Shunt dysfunction happened in 4 (16.0%) patients. The original symptoms reoccurred in 2 patients (8.0%) and the remaining patients were diagnosed by routine CT or US examination. Three patients recovered after shunt revision with stent implantation or balloon angioplasty, while one patient refused any further therapy except oral medication. This patient suffered from the first episode of rebleeding 36 months after PTIPS. Hepatic encephalopathy developed in 2 (8.0%) patients, 1 patient recovered after medical treatment, while the other who developed Grade 3 hepatic encephalopathy recovered after implanting a smaller cover stent. The remaining patients were asymptomatic with patent shunts. Conclusion PTIPS was a feasible, safe, and efficacious treatment for portal hypertension due to chronic portal vein occlusion after splenectomy. Key words: Venous thrombosis; Portal vein, hypertension; Splenectomy; Portosystemic shunt

About this research paper

What this paper is about

Objective To study the feasibility and efficacy of percutaneous transhepatic intrahepatic portosystemic shunt (PTIPS) in patients with portal hypertension due to chronic portal vein occlusion after splenectomy. Methods 27 patients who had portal hypertension due to chronic portal vein occlusion after splenectomy underwent PTIPS between December 2010 and March 2015. These patients were enrolled in this retrospective study. The success rates, efficacy, and complications were evaluated. Significance in the differences in the portosystemic pressure gradient (PPG) as measured before and after PTIPS procedure was assessed. Results PTIPS was successfully carried out in 25 patients but failed in 2. No fatal procedural complications were observed. The mean PPG dropped from (22.3±5.7) mmHg to (12.4±3.1) mmHg after successful PTIPS (1 mmHg=0.133 kPa, P<0.05). The median follow-up in the 25 patients with successful PTIPS were 22 months and there were 3 (12.0%) deaths from liver failure due to severe cirrhosis, and 1 death (4.0%) from stroke during the follow-up period. Shunt dysfunction happened in 4 (16.0%) patients. The original symptoms reoccurred in 2 patients (8.0%) and the remaining patients were diagnosed by routine CT or US examination. Three patients recovered after shunt revision with stent implantation or balloon angioplasty, while one patient refused any further therapy except oral medication. This patient suffered from the first episode of rebleeding 36 months after PTIPS. Hepatic encephalopathy developed in 2 (8.0%) patients, 1 patient recovered after medical treatment, while the other who developed Grade 3 hepatic encephalopathy recovered after implanting a smaller cover stent. The remaining patients were asymptomatic with patent shunts. Conclusion PTIPS was a feasible, safe, and efficacious treatment for portal hypertension due to chronic portal vein occlusion after splenectomy. Key words: Venous thrombosis; Portal vein, hypertension; Splenectomy; Portosystemic shunt

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To study the feasibility and efficacy of percutaneous transhepatic intrahepatic portosystemic shunt (PTIPS) in patients with portal hypertension due to chronic portal vein occlusion after splenectomy. Methods 27 patients who had portal hypertension due to chronic portal vein occlusion after splenectomy underwent PTIPS between December 2010 and March 2015. These patients were enrolled in this retrospective study. The success rates, efficacy, and complications were evaluated. Significance in the differences in the portosystemic pressure gradient (PPG) as measured before and after PTIPS procedure was assessed. Results PTIPS was successfully carried out in 25 patients but failed in 2. No fatal procedural complications were observed. The mean PPG dropped from (22.3±5.7) mmHg to (12.4±3.1) mmHg after successful PTIPS (1 mmHg=0.133 kPa, P<0.05). The median follow-up in the 25 patients with successful PTIPS were 22 months and there were 3 (12.0%) deaths from liver failure due to severe cirrhosis, and 1 death (4.0%) from stroke during the follow-up period. Shunt dysfunction happened in 4 (16.0%) patients. The original symptoms reoccurred in 2 patients (8.0%) and the remaining patients were diagnosed by routine CT or US examination. Three patients recovered after shunt revision with stent implantation or balloon angioplasty, while one patient refused any further therapy except oral medication. This patient suffered from the first episode of rebleeding 36 months after PTIPS. Hepatic encephalopathy developed in 2 (8.0%) patients, 1 patient recovered after medical treatment, while the other who developed Grade 3 hepatic encephalopathy recovered after implanting a smaller cover stent. The remaining patients were asymptomatic with patent shunts. Conclusion PTIPS was a feasible, safe, and efficacious treatment for portal hypertension due to chronic portal vein occlusion after splenectomy. Key words: Venous thrombosis; Portal vein, hypertension; Splenectomy; Portosystemic shunt

Key concepts: Medicine, Portal hypertension, Surgery, Splenectomy, Cirrhosis, Transjugular intrahepatic portosystemic shunt, Portosystemic shunt, Percutaneous

Related papers

Back to paper searchBrowse research topicsOriginal source
Percutaneous transhepatic intrahepatic portosystemic shunt for treatment of portal hypertension due to chronic portal vein occlusion after splenectomy — Research Paper | ScholarLens